Abstract: OBJECTIVES: The aim of this study was to investigate the dual blood supply of non-small cell lung cancer (NSCLC) and its association with tumor subtype, size, and stage, using computed tomography perfusion (CTP). MATERIALS AND METHODS: A total of 54 patients (median age, 65 years; range, 42-79 years; 15 women, 39 men) with suspected lung cancer underwent a CTP scan of the lung tumor. Pulmonary and bronchial vasculature regions of interest were used to calculate independently CTP parameters (blood flow [BF], blood volume [BV], and mean transit time [MTT]) of the tumor tissue. The mean and maximum pulmonary and bronchial perfusion indexes (PImean and PImax) were calculated. The tumoral volume and the largest tumoral diameter were assessed. Differences in CTP parameters and indexes among NSCLC subtypes, tumor stages and tumor dimensions were analyzed using non-parametric tests. RESULTS: According to biopsy, 37 patients had NSCLC (22 adenocarcinomas [ACs], 8 squamous cell carcinomas [SCCs], 7 large-cell carcinomas [LCC]). The mean bronchial BF/pulmonary BF, bronchial BV/pulmonary BV, and bronchial MTT/pulmonary MTT was 41.2 ± 30.0/36.9 ± 24.2 mL/100 mL/min, 11.4 ± 9.7/10.4 ± 9.4 mL/100 mL, and 11.4 ± 4.3/14.9 ± 4.4 seconds, respectively. In general, higher bronchial BF than pulmonary BF was observed in NSCLC (P = 0.014). Using a tumoral volume cutoff of 3.5 cm, a significant difference in pulmonary PImax was found (P = 0.028). There was a significantly higher mean pulmonary BF in LCCs and SCCs compared with ACs (P = 0.018 and P = 0.044, respectively), whereas the mean bronchial BF was only significantly higher in LCCs compared with ACs (P = 0.024). Correspondingly, the PImax was significantly higher in LCCs and SCCs than in ACs (P = 0.001 for both). Differences between bronchial and pulmonary PImean and PImax among T stages and Union Internationale Contre le Cancer stages were not statistically significant (P values ranging from 0.691 to 0.753). CONCLUSIONS: The known dual blood supply of NSCLC, which depends on tumor size and histological subtype, is reflected in CTP parameters, with parameters depending both on tumor size and histological subtype. This has to be accounted for when analyzing NSCLC with CTP.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.
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Objectives: The aim of this study was to investigate the dual blood supply of non-small cell lung cancer (NSCLC) and its association with tumor subtype, size, and stage, using computed tomography perfusion (CTP). Materials and Methods: A total of 54 patients (median age, 65 years; range, 42-79 years; 15 women, 39 men) with suspected lung cancer underwent a CTP scan of the lung tumor. Pulmonary and bronchial vasculature regions of interest were used to calculate independently CTP parameters (blood flow [BF] , blood volume [BV] , and mean transit time [MTT] ) of the tumor tissue. The mean and maximum pulmonary and bronchial perfusion indexes (PI mean and PI max ) were calculated. The tumoral volume and the largest tumoral diameter were assessed. Differences in CTP parameters and indexes among NSCLC subtypes, tumor stages and tumor dimensions were analyzed using non-parametric tests.
Results: According to biopsy, 37 patients had NSCLC (22 adenocarcinomas [ACs], 8 squamous cell carcinomas [SCCs], 7 large-cell carcinomas [LCC]).
The mean bronchial BF/pulmonary BF, bronchial BV/pulmonary BV, and bronchial MTT/pulmonary MTT was 41.2 ± 30.0/36.9 ± 24.2 mL/100 mL/min, 11.4 ± 9.7/10.4 ± 9.4 mL/100 mL, and 11.4 ± 4.3/14.9 ± 4.4 seconds, respectively. In general, higher bronchial BF than pulmonary BF was observed in NSCLC (P = 0.014). Using a tumoral volume cutoff of 3.5 cm 3 , a significant difference in pulmonary PI max was found (P = 0.028). There was a significantly higher mean pulmonary BF in LCCs and SCCs compared with ACs (P = 0.018 and P = 0.044, respectively), whereas the mean bronchial BF was only significantly higher in LCCs compared with ACs (P = 0.024). Correspondingly, the PI max was significantly higher in LCCs and SCCs than in ACs (P = 0.001 for both). Differences between bronchial and pulmonary PI mean and PI max among T stages and Union Internationale Contre le Cancer stages were not statistically significant (P values ranging from 0.691 to 0.753). Conclusions: The known dual blood supply of NSCLC, which depends on tumor size and histological subtype, is reflected in CTP parameters, with parameters depending both on tumor size and histological subtype. This has to be accounted for when analyzing NSCLC with CTP.
Key Words: computed tomography, perfusion, lung neoplasms, multimodal imaging, medical oncology (Invest Radiol 2015;00: 00-00) T hroughout the world, lung cancer still accounts for more deaths than any other cancer does. More than 200,000 new cases and approximately 160,000 deaths, accounting for more than one quarter of all cancer-related deaths, are expected in the United States for 2014.
1 Non-small cell lung cancer (NSCLC) constitutes most of lung cancer. In most patients, the disease is already advanced at the time of the initial diagnosis, and hence, palliative radiation therapy and chemotherapy are initiated as first-line regimens. 2, 3 The proliferation of new blood vessels, originating from the existing vascular system, is needed both for tumor growth and metastatic dissemination. [4] [5] [6] Monoclonal antibodies, such as bevacizumab, targeting vascular endothelial growth factor to inhibit tumoral angiogenesis, suppress tumor growth. Such targeted drugs are increasingly used in combination with standardized platinum-based chemotherapy. 2, 7 Patient treatment hence becomes more individualized to tumor biology, taking into account angiogenic status, which still needs to be learned and understood. 7, 8 The traditional monitoring of therapeutic effects, being based on morphological criteria on computed tomography (CT), may lead to a misinterpretation of antiangiogenic effects. 9, 10 Hence, the evolving therapeutic field of vascular-modulating drugs requires new noninvasive methods for assessing tumor vascularity in vivo. [11] [12] [13] [14] [15] In 1967, Milne 16 showed that lung tumors may have a dual blood supply by the pulmonary and the aortic system, with a trend toward histological type-specific circulatory pattern. The advent of CT perfusion (CTP) within the last decade allowed for a direct, noninvasive quantification of the vascular function. 17, 18 Functional parameters, derived from the assessment of peak tumor enhancement over time in the tissue during the CTP scan, give information about blood volume (BV), blood flow (BF), and mean transit time (MTT) within the network of tumoral neovascularity, as well as the rate of abnormal leakage into the extracellular space, due to the vascular hyperpermeability in the abnormal neovessel wall. 5, 19 One of the first applications for the assessment of lung lesions with CTP was pulmonary nodules, particularly in comparison with 18 F-fluoro-2-deoxy-D-glucose positron emission tomography/ CT (PET/CT). 20 Cutoff values have been defined for several CTP parameters to differentiate benign from malignant pulmonary nodules, with lower perfusion index (PI) and higher BF and BV obtained in malignancy. 21, 22 Similar accuracy of CTP and fluoro-2-deoxy-D-glucose-PET/CT was confirmed in the meta-analysis by Cronin et al. 23 Several studies have addressed differences of CTP parameters among histological lung cancer subtypes, assessing them with a single-input CTP analysis of either the pulmonary or the bronchial arterial system. [24] [25] [26] [27] Computed tomography perfusion in lung cancer remains a technical challenge, particularly due to breathing motion over time. 28 Furthermore, a true separation of pulmonary and bronchial BF using a CTP analysis is technically not possible at this time because blood from both vascular inputs is mixed within lesions at a microscopic level, precluding both spatial and temporal separation. Despite these difficulties, Yuan et al 22 recently demonstrated that a dual-input maximum slope CTP analysis is valuable in NSCLC. However, many centers do not fulfill the hardware and software requirements for such a dual-input analysis and rely on either single-input pulmonary or bronchial CTP assessment. Currently, there is no universally accepted consensus regarding into which vascular system the arterial input region of interest (ROI) should be placed, 27, 29, 30 and either method's results are used interchangeably. The differences in pulmonary circulation-derived and bronchial circulation-derived analyses are still unclear, and a direct comparison of CTP parameters derived with these two different methods is problematic. Besides, information about the association of pulmonary-derived and bronchial-derived CTP parameters with tumor size, volume, and stage in different NSCLC subtypes is still limited.
We hypothesized that values of CTP parameters obtained by pulmonary or bronchial analysis might be different depending on tumor type, stage, and size. Such differences would have to be accounted for analyzing NSCLC using CTP with either vasculature approach in a clinical setup. Thus, the purpose of this study was to investigate the relevance of pulmonary and bronchial ROI placement in the CTP assessment of dually blood-supplied NSCLC and its association with histological subtypes, tumor size, and tumor stage.
MATERIALS AND METHODS

Study Population
A total of 54 patients (median age, 61 years; range, 42-79 years; 15 women, 39 men) with suspected lung cancer being referred to our PET/CT center for baseline staging were prospectively enrolled in this ethical committee-approved study between January 2012 and December 2012. All patients provided signed informed consent before the examinations. All subjects underwent a CTP scan of the suspected lung tumor. Exclusion criteria were unwillingness to undergo the CTP scan, renal insufficiency in nondialyzed patients, pregnancy, untreated hyperthyroidism, severe respiratory dysfunction, and known previous reaction after administration of iodinated contrast medium. A definitive histopathological diagnosis was obtained in all subjects by CT-guided biopsy, bronchofibroscopic biopsy, or tumor resection (median time interval, 6 days after CTP scan; range, 0-18 days). Thirteen patients were excluded after the scan because histology results revealed lesions other than NSCLC (small cell lung cancer, 5 patients; inflammatory myofibroblastic pseudotumor, 1 patient; cavitating staphylococcal pneumonia, 1 patient; streptococcal pneumonia, 1 patient; pulmonary sequester, 1 patient; lymphoma, 1 patient; sarcoma, 1 patient; pulmonary hamartoma, 1 patient; and tularemia, 1 patient). In 4 patients, the subsequent combined pulmonary and bronchial CTP analysis was not possible because of technical problems. Finally, 37 patients were eligible for analysis. The NSCLC subtype, tumor size, volume, and stage were recorded in all patients. The standard of reference consisted of postsurgical histopathology results in 13 subjects, providing of pathological tumor stage. In the remaining 24 patients, biopsy-derived histopathology and clinical tumor stage were used.
CT Perfusion Protocol
Patients were advised to resume shallow breathing for the entire duration of the scan. All scans were performed on a 256-slice CT scanner (Somatom Definition Flash, Siemens Healthcare, Erlangen, Germany). The Z-axis scanning length was 7 cm. This relatively large scan length was chosen to cover the whole tumor as well as major pulmonary and bronchial vessels in every patient. The tube current was fixed to 100 mAs, and the tube voltage set to 100 kV. An automatic exposure control was not used. The duration of the whole CTP scan was 60 seconds, with a rotation time of 1 second, and 1 scan per second. The volume CT dose index and dose-length product were 193.1 mGy and 1707 mGy cm, respectively, corresponding to a calculated effective dose of 23.9 mSv. The CTP scanning was started with a delay of 3 seconds after the initiation of the injection of 40 mL of iodinated contrast medium (Ultravist 370, Bayer Healthcare, Leverkusen, Germany) at a flow rate of 4.5 mL/s. The contrast medium was injected into an antecubital vein by a dualhead pump injection device (Stellant D, Medrad, Warrendale, PA), followed by a flush of 50 mL of saline at 4.5 mL/s. This rather lengthy protocol was chosen to ensure a high reproducibility of perfusion parameters. 31 The slice-collimation was set to 64 Â 0.6 mm. The reconstruction increment was 3 mm with a 5-mm slice width. Image reconstruction was performed with a 512 Â 512 pixel matrix and medium smooth B30f kernel.
Data Postprocessing and Image Analysis
For postprocessing and analysis, the reconstructed images were transferred to a commercially available computer workstation with dedicated perfusion software (Leonardo; Syngo Volume Perfusion CT Body, Siemens Healthcare). All procedures were carried out by 1 boardcertified radiologist (D.N.) with 6 years of experience in chest imaging. After computerized motion correction, a semiautomatic freehand segmentation of the tumor tissue volume over time was performed. To investigate the pulmonary and bronchial CTP parameters independently, an elliptical ROI was placed in the pulmonary trunk and in the descending aorta at the level of the bronchial arteries, respectively. If the pulmonary trunk was not covered by the CTP volume, the left or right pulmonary artery was chosen. Time density curves of tissue with different peak times were calculated, depending on whether a pulmonary-based or bronchialbased examination was performed.
Pulmonary and bronchial CTP parameters, including specifically the mean BF, BV, and MTT of the tumor tissue, as well as the maximum BF (BF max ), were calculated automatically by the software (Figs. 1-3) . The mean PI (PI mean ) and the maximum PI (PI max ) for both the pulmonary and bronchial blood circulation were calculated according to the following formulas:
The longest diameter of the tumor was determined based on the morphological CT data set. The tumor volume was segmented semiautomatically using a dedicated volumetry software (Myrian, Intrasense, Paris, France).
Statistical Analysis
All statistical analyses were performed using IBM SPSS Statistics 19.0.1 (SPSS Inc, Chicago, IL). Differences in pulmonary circulationderived CTP parameters and bronchial circulation-derived CTP parameters and indexes were analyzed using the Wilcoxon signed-ranks test. Differences in CTP parameters and indexes among NSCLC subtypes, tumor stages, and among small and large tumors were analyzed using the Wilcoxon signed-ranks test or the Kruskal-Wallis test. Correlation analyses were performed using Spearman correlation coefficient to analyze the relationship of CTP parameters and indexes with the tumor diameter, tumor volume, T stage, and Union Internationale Contre le Cancer stage.
RESULTS
Histology results revealed that our study cohort consisted of 22 adenocarcinomas (ACs), 8 squamous cell carcinomas (SCCs), and 7 large-cell carcinomas (LCCs). During therapy, 13 patients (8 with AC, 4 with SCC, 1 with LCC) underwent curative surgery and adjuvant radiochemotherapy, providing pathological TNM status analysis. Thirteen patients underwent primary curative radiochemotherapy; 10, palliative
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Investigative Radiology • Volume 00, Number 00, Month 2015 chemotherapy; and 1, neoadjuvant therapy and surgery. In these 24 patients, only clinical TNM was available. The tumor stage was T1 in 4 patients, T2 in 25 patients, T3 in 4 patients, and T4 in 4 patients. More detailed characteristics of the study population are given in Table 1 . For all tumors, the mean pulmonary/bronchial BF was 36.9/41.2 mL/100 mL/min, the maximum pulmonary/bronchial BF was 56.4/64.6 mL/100 mL/min, the mean pulmonary/bronchial BV was 10.4/11.4 mL/100 mL, and the mean pulmonary/bronchial MTT was 14.9/ 11.4 seconds.
Overall, the bronchial circulation-derived BF was significantly higher than the pulmonary circulation-derived BF (P = 0.014) ( Table 2 ). Within the subanalysis of histological subtypes of NSCLC, only the BF max of AC was different depending on the type of assessment, albeit with borderline significance (P = 0.049) ( Table 2) . Such a trend toward higher bronchial than pulmonary BF could also be seen for the remaining subgroups SCC and LCC, however, without reaching statistical significance (P = 0.401 and P = 0.237, respectively). The significant differences in MTT measured with both methods (P values ranging from <0.001 to 0.018) are a direct consequence of our approach and are listed in Table 2 only for the sake of completeness. A detailed overview of CTP parameters of NSCLC subtypes is given in Table 3 . Pulmonary-and bronchial-derived BFs were both significantly higher in LCC than in AC (P = 0.018, P = 0.024, respectively). Pulmonary PI max was significantly higher in LCC and SCC than in AC (P = 0.001, each) (Fig. 4) . Differences in PI mean and PI max among T stages and Union Internationale Contre le Cancer stages were statistically not significant (P values ranging from 0.691 to 0.753), as well as differences between other CTP parameters. Using a volume threshold of 3.5 cm 3 (tumors <3.5 cm 3 , n =15; tumors >3.5 cm 3 , n =22), the pulmonary PI max was found to be significantly different (P = 0.028) (Fig. 5) , whereas no differences were found for the bronchial BF max and pulmonary BF max (P = 0.646, P = 0.805, respectively). Furthermore, no discriminative threshold could be found for the tumor diameter.
DISCUSSION
It is known that NSCLCs have a dual blood supply, with contributions both from the pulmonary and the bronchial vasculature. 16 Consistent with the results of the recent study by Yuan et al, 22 our findings show that, in NSCLC, the bronchial contribution is higher than the pulmonary contribution. In addition, we have now demonstrated that there are also differences depending on the NSCLC subtype: LCC shows higher bronchial and pulmonary BV and BF compared with AC and SCC. And the pulmonary PI max was found to be significantly higher in LCC and SCC compared with AC.
In general, higher perfusion is believed to be related to more aggressive tumor features, such as local invasiveness and metastatic capability. Our results likely reflect the biological nature of LCC, which is known to be a poorly differentiated tumor and clinically often shows a similar behavior as small cell lung cancer, concerning its aggressiveness and poor long-term survival. [32] [33] [34] [35] Correspondingly, Fraioli and 36 recently showed that the comparably high BF of LCC shows the best response of all NSCLC subtypes to antiangiogenic treatment. We found significant differences in pulmonary PI max using a tumor volume cutoff of 3.5 cm 3 , with higher pulmonary PI max in larger tumors. This implies an increase in pulmonary blood supply with growing tumor size. Our findings correspond reasonably to the results of the study by Kiessling et al, 37 who found lower perfusion in tumors larger than 50 mm 3 , using a bronchial arterial system analysis. Tumor volume certainly reflects the actual tumor size more exactly than does the maximum diameter alone. Given an ellipsoid-shaped tumor, it is obvious that the maximum diameter might not correctly reflect the actual tumor volume. 38 This may be one likely reason we could not find a discriminative cutoff for the maximum tumor diameter.
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In 1 of the first studies on this topic, Milne 16 demonstrated that the pulmonary circulation supplies the surface of the tumor, whereas the central portion is supplied by the bronchial artery system. With increasing tumor volume, hypoxia may occur in the central parts of the tumor as a result of insufficient blood supply due to an increasing diffusion distance between blood vessels and tumor cells, 26, 39 explaining the need to recruit additional blood vessels from the pulmonary system, which carries deoxygenated blood but has a much larger cross-sectional area than the bronchial system does. Hence, our results provide further evidence for the theory that NSCLCs have a tendency to recruit more new blood vessels from the pulmonary system than from the bronchial system to grow. It however remains unclear if growing tumors might not just surround pulmonary vessels recruiting them, rather than constituting real angiogenesis originating from pulmonary vessels.
If interventional endovascular therapy is contemplated in an NSCLC patient, knowledge about the PI max may provide guidance for choosing a transbronchial or a transpulmonary approach. Transarterial chemoembolization has been used successfully for years for the treatment of hepatic malignancies 40 and has recently gained attention as a minimally invasive approach for treating NSCLC. 41 Recent studies demonstrated that the transpulmonary chemoembolization of different malignant lung lesions yielded a favorable tumor response without major complications. [41] [42] [43] It is now considered a well-tolerated palliative treatment option in patients with lung metastases. 44 However, today, no clear recommendation exists in which case a transpulmonary or transbronchial approach should be attempted. In this context, our results would suggest a preferred transpulmonary approach in tumors larger than 3.5 cm 3 , especially in LCC and SCC, and a transbronchial approach in tumors smaller than 3.5 cm 3 , especially in AC. Although the response evaluation criteria in solid tumors were developed to assess tumoral response to cytotoxic agents, these may not properly reflect tumoral changes because of new antiangiogenic drugs. 7, 45 Computed tomography perfusion might represent a clinical tool to assess the "behavior" of tumoral angiogenesis under targeted antiangiogenic therapy. This concept has been addressed by several previous studies.
9,15,46-48 Tacelli et al 19, 36 showed a significant reduction in total tumor vascular volume during treatment with chemotherapy using anti-vascular endothelial growth factor drugs. Fraioli et al 19, 36 demonstrated a significant difference in BF and BV in LCC patients for partial response and progressive disease. Although we did not address therapeutic effects, the results of our study indicate that both histological subtype and tumor volume likely should be taken into account when assessing tumoral treatment response using CTP. Further studies are needed to address treatment-induced effects on either blood supply, to define a potential role of pulmonary and/or bronchial CTP assessment for therapy monitoring.
Because we applied a tube voltage of 100 kVand found no bothersome beam-hardening, we believe that the voltage might even be reduced further for CTP studies, especially concerning the lung, to increase the sensitivity to the contrast agent and to reduce both dose exposure and contrast agent administered to the patient.
Our study has several limitations. Our approach was not able to directly and independently measure the contribution of the pulmonary and bronchial vasculature to the overall tumor perfusion. This was, however, not our goal because we aimed at identifying differences in CTP parameters depending on the type of the arterial input ROI placement. Most of our subjects had AC, which means that the overall results for NSCLC were dependent largely upon this histological subtype. This, however, does not affect the subanalyses carried out for all histological subtypes, although LCC and SCC numbers were comparably small. Tumor stage was somewhat skewed according to NSCLC subtypes, with LCC patients having by trend more advanced stages. This may also have influenced our results. As well, most of the reported tumor stages were clinical and not pathological. 
